Daiichi Sankyo Company, Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hiroyuki Okuzawa
- Full Time Employees
- 18,726
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 3-5-1, Nihonbashi-honcho Tokyo Japan 103-8426
- IPO Date
- Dec 12, 2008
- Website
- daiichisankyo.com
- Similar Companies
- Business
- Daiichi Sankyo Company, Limited, a global pharmaceutical company headquartered in Tokyo, Japan, and founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, discovers, develops, manufactures and commercializes innovative prescription medicines focused primarily on oncology, cardiovascular-metabolic disease and other therapeutic areas including neurology, pain management and rare diseases; key products include the antibody-drug conjugate Enhertu (trastuzumab deruxtecan) approved in over 60 countries for HER2-positive breast cancer, over 55 countries for HER2-low breast cancer, multiple countries for HER2-mutant non-small cell lung cancer and gastric cancer, and the US for certain HER2-positive solid tumors; Vanflyta (quizartinib), an FLT3 inhibitor approved in the US, EU/UK and Japan for newly diagnosed FLT3-ITD positive acute myeloid leukemia; Turalio (pexidartinib) for tenosynovial giant cell tumor in the US; Datroway (datopotamab deruxtecan) approved in the US, Japan and Russia for certain breast cancers and EGFR-mutated NSCLC; cardiovascular treatments such as Savaysa/Lixiana (edoxaban), a direct factor Xa inhibitor marketed in the US, EU, Japan and Asia/South/Central America (ASCA); Injectafer (ferric carboxymaltose) for iron deficiency anemia; Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ezetimibe combination) for cholesterol reduction in the EU; prasugrel (anti-platelet agent); olmesartan medoxomil; esaxerenone (antihypertensive); teneligliptin and canagliflozin for type 2 diabetes; denosumab for osteoporosis and bone metastases; mirogabalin for neuropathic pain; lacosamide for seizures; galcanezumab and lasmiditan for migraine; and vaccines including COVID-19, influenza and measles-rubella formulations. The company operates in more than 30 countries and regions worldwide with subsidiaries including Daiichi Sankyo, Inc. in Basking Ridge, New Jersey, USA; Daiichi Sankyo Europe GmbH in Munich, Germany, overseeing affiliates in 14 European countries plus Canada and Nordics representation; and production sites such as Pfaffenhofen an der Ilm, Germany, which manufactures active pharmaceutical ingredients and solid-dose forms shipped to over 50 countries; it employs over 19,000 people globally and owns American Regent, a US-based subsidiary formerly Luitpold. Recent developments include a strategic alliance with Merck & Co., Inc. announced in 2025 for global development and commercialization of MK-6070, a DLL3-targeting T-cell engager, and expansion of their prior DXd antibody-drug conjugate collaboration covering patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd/DS-6000); a approximately €1 billion (US$1.08 billion) investment announced in February 2024 to expand the Pfaffenhofen site into an international innovation center for ADC production and development by 2030, adding at least 350 jobs and new ADC facilities by end-2026 alongside cardiovascular capacity enhancements; an absorption-type merger of subsidiaries Daiichi Sankyo Propharma and Daiichi Sankyo Chemical Pharma effective April 1, 2025, to stabilize ADC supply and accelerate new modalities; plans to relocate its Tokyo global headquarters near Nihonbashi Bridge in fall 2027 to enhance office functionality, productivity and support for diverse work styles while relocating the Daiichi Sankyo Kusuri Museum; and ongoing advancement of its oncology-focused pipeline toward FY2025 goals as a Global Pharma Innovator with Competitive Advantage in Oncology.
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
New Strong Sell Stocks for February 25th
Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued
SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Daiichi Sankyo Company, Limited (DSNKY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
CPRX or DSNKY: Which Is the Better Value Stock Right Now?